Arginine vasopressin vs. terlipressin in the treatment of shock states

Best Practice and Research: Clinical Anaesthesiology

Volumn 22, Issue 2, 2008, Pages 359-368

  Singer, Mervyn ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

septic shock; shock; terlipressin; vascular hyporeactivity; vasopressin

Indexed keywords

ARGIPRESSIN; CATECHOLAMINE; CORTICOSTEROID; DOBUTAMINE; GLYCERYL TRINITRATE; LYPRESSIN; METHYLENE BLUE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PROSTACYCLIN; PROSTAGLANDIN E1; TERLIPRESSIN; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ACROCYANOSIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; ELECTROLYTE DISTURBANCE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; INTESTINE ISCHEMIA; LOW DRUG DOSE; METABOLIC ACIDOSIS; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; UNSPECIFIED SIDE EFFECT;

ANIMALS; ARGININE VASOPRESSIN; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LYSINE VASOPRESSIN; SHOCK; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 44949156224     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2008.03.005     Document Type: Review

References (69)

1. Padkin A., Goldfrad C., Brady A.R., et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Critical Care Medicine 31 (2003) 2332-2338
2. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. The New England Journal of Medicine 348 (2003) 1546-1554
3. Available from:. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/finaldeaths03/finaldeaths03.htm
4. Annane D., Bellissant E., and Cavaillon J.M. Septic shock. The Lancet 365 (2005) 63-78
5. Rudiger A., and Singer M. Sepsis-induced cardiac depression. Critical Care Medicine 35 (2007) 1599-1608
6. O'Brien A.J., Wilson A.J., Singer M., and Clapp L. Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model. British Journal of Pharmacology 133 (2001) 351-360
7. ATP channels in sepsis. Cardiovascular Research 72 (2006) 220-230
8. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997) 1122-1125
9. Sharshar T., Blanchard A., Paillard M., et al. Circulating vasopressin levels in septic shock. Critical Care Medicine 31 (2003) 1752-1758
10. Wilson M.F., Brackett D.J., Hinshaw L.B., et al. Vasopressin release during sepsis and septic shock in baboons and dogs. Surgery Gynecology & Obstetrics 153 (1981) 869-872
11. Lopez A., Lorente J.A., Steingrub J., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Critical Care Medicine 32 (2004) 21-30
12. Holmes C.L., Walley K.R., Chittock D.R., et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Medicine 27 (2001) 1416-1421
13. Russell J.A., Walley K.R., Singer J., et al., for the VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. The New England Journal of Medicine 358 (2008) 877-887
14. Barrett L., Singer M., and Clapp L.H. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Critical Care Medicine 35 (2007) 33-40
15. Nilsson G., Lindblom P., Ohlin M., et al. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs under Experimental and Clinical Research 16 (1990) 307-314
16. Forsling M.L., Aziz L.A., Miller M., et al. Conversion of triglycylvasopressin to lysine-vasopressin in man. The Journal of Endocrinology 85 (1980) 237-244
17. Freeman J.G., Cobden I., Lishman A.H., and Record C.O. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. The Lancet ii (1982) 66-68
18. Walker S., Stiehl A., Raedsch R., and Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology 6 (1986) 112-115
19. Levacher S., Letoumelin P., Pateron D., et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. The Lancet 346 (1995) 865-868
20. Hadengue A., Gadano A., Moreau R., et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology 29 (1998) 565-570
21. Uriz J., Ginès P., Cárdenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology 33 (2000) 43-48
22. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122 (2002) 923-930
23. Boccara G., Ouattara A., Godet G., et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 98 (2003) 1338-1344
24. Leone M., Charvet A., Delmas A., et al. Terlipressin: a new therapeutic for calcium-channel blocker overdose. Journal of Critical Care 20 (2005) 114-115
25. Zuidema X., Dünser M.W., Wenzel V., et al. Terlipressin as an adjunct vasopressor in refractory hypotension after tricyclic antidepressant intoxication. Resuscitation 72 (2007) 319-323
26. Salluh J.I., Martins G.A., Santino M.S., et al. Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury. Acta Anaesthesiologica Scandinavica 51 (2007) 505-508
27. Rocq N., Favier J.C., Plancade D., et al. Successful use of terlipressin in post-cardiac arrest resuscitation after an epinephrine-resistant anaphylactic shock to suxamethonium. Anesthesiology 107 (2007) 166-167
28. Matok I., Vardi A., Augarten A., et al. Beneficial effects of terlipressin in prolonged pediatric cardiopulmonary resuscitation: a case series. Critical Care Medicine 35 (2007) 1161-1164
29. Vinayak B.C., Birchall M.A., Donovan B., and Stafford N.D. A randomized double-blind trial of glypressin in the management of acute epistaxis. Rhinology 31 (1993) 131-134
30. Vernersson E., Palmer B., and Aberg M. Triglycyl-lysine-vasopressin or lysine-vasopressin in early excision of burns. An experimental study comparing the effects on blood loss, hemodynamics and renal function. Scandinavian Journal of Plastic and Reconstructive Surgery 18 (1984) 285-290
31. Garner W.L., Thomson P.D., Moore N.P., et al. Effect of triglycyl-lysine-vasopressin on skin blood flow and blood loss during wound excision in patients with burns. The Journal of Burn Care & Rehabilitation 14 (1993) 458-460
32. Scharte M., Meyer J., Van Aken H., and Bone H.G. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Critical Care Medicine 29 (2001) 1756-1760
33. O'Brien A., Clapp L., and Singer M. Terlipressin for norepinephrine-resistant septic shock. The Lancet 359 (2002) 1209-1210
34. Tsuneyoshi I., Yamada H., Kakihana Y., et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Critical Care Medicine 29 (2001) 487-493
35. Morelli A., Rocco M., Conti G., et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Medicine 30 (2004) 597-604
36. Leone M., Albanèse J., Delmas A., et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 22 (2004) 314-319
37. Albanèse J., Leone M., Delmas A., and Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Critical Care Medicine 33 (2005) 1897-1902
38. Klein M., Weksler N., Borer A., et al. Terlipressin facilitates transport of septic patients treated with norepinephrine. The Israel Medical Association Journal 8 (2006) 691-693
39. Jolley D.H., De Keulenaer B.L., Potter A., and Stephens D.P. Terlipressin infusion in catecholamine-resistant shock. Anaesthesia and Intensive Care 31 (2003) 560-564
40. Fellahi J.L., Bénard P., Daccache G., et al. Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin?. Annales Francaises d'Anesthesie et de Reanimation 22 (2003) 631-634
41. Matok I., Leibovitch L., Vardi A., et al. Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatric Critical Care Medicine 5 (2004) 116-118
42. Rodríguez-Núñez A., Fernández-Sanmartín M., Martinón-Torres F., et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Medicine 30 (2004) 477-480
43. Peters M.J., Booth R.A., and Petros A.J. Terlipressin bolus induces systemic vasoconstriction in septic shock. Pediatric Critical Care Medicine 5 (2004) 112-115
44. Matok I., Vard A., Efrati O., et al. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock 23 (2005) 305-310
45. Rodríguez-Núñez A., López-Herce J., Gil-Antón J., et al., for the RETSPED Working Group of the Spanish Society of Pediatric Intensive Care. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Critical Care (London, England) 10 (2006) R20
46. Meyer S., Gortner L., McGuire W., et al. Vasopressin in catecholamine-refractory shock in children. Anaesthesia 63 (2008) 228-234
47. Yildizdas D., Yapicioglu H., Celik U., et al. Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Medicine 34 (2008) 511-517
48. Medel J., Boccara G., Van de Steen E., et al. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?. Anesthesia & Analgesia 93 (2001) 53-55
49. Schmitt W., Wagner-Thiessen E., and Lux G. Ischaemic colitis in a patient treated with glypressin for bleeding oesophageal varices. Hepatogastroenterology 34 (1987) 134-136
50. Foresti V., Parisio E., Ungaro A., et al. Terlipressin-induced metabolic acidosis. Recenti Progressi in Medicina 82 (1991) 240-241
51. Stéphan F., and Paillard F. Terlipressin-exacerbated hypokalaemia. The Lancet 351 (1998) 1249-1250
52. Dunwoodie E., and Jowett S. Terlipressin causing a hyponatraemic seizure. Scandinavian Journal of Gastroenterology 42 (2007) 665
53. Lee J.S., Lee H.S., Jung S.W., et al. A case of peripheral ischemic complication after terlipressin therapy. The Korean Journal of Gastroenterology 47 (2006) 454-457
54. Donnellan F., Cullen G., Hegarty J.E., and McCormick P.A. Ischaemic complications of Glypressin in liver disease: a case series. British Journal of Clinical Pharmacology 64 (2007) 550-552
55. Borrego R., López-Herce J., Mencía S., et al. Severe ischemia of the lower limb and of the intestine associated with systemic vasoconstrictor therapy and femoral arterial catheterization. Pediatric Critical Care Medicine 7 (2006) 267-269
56. Boerma E.C., van der Voort P.H., and Ince C. Sublingual microcirculatory flow is impaired by the vasopressin-analogue terlipressin in a patient with catecholamine-resistant septic shock. Acta Anaesthesiologica Scandinavica 49 (2005) 1387-1390
57. Hansen E.F., Strandberg C., Højgaard L., et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. Journal of Hepatology 30 (1999) 503-510
58. Blei A.T., Groszmann R.J., Gusberg R., and Conn H.O. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Digestive Diseases and Sciences 25 (1980) 688-694
59. Asfar P., Pierrot M., Veal N., et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Critical Care Medicine 31 (2003) 215-220
60. Asfar P., Hauser B., Iványi Z., et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Critical Care Medicine 33 (2005) 373-380
61. Westphal M., Stubbe H., Sielenkämper A.W., et al. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Medicine 29 (2003) 301-308
62. Bröking K., Lange M., Morelli A., et al. Employing dobutamine as a useful agent to reverse the terlipressin-linked impairments in cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 29 (2008) 71-77
63. Escorsell A., Bandi J.C., Moitinho E., et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. Journal of Hepatology 26 (1997) 621-627
64. Freeman J.G., Barton J.R., and Record C.O. Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man. Alimentary Pharmacology & Therapeutics 2 (1988) 361-367
65. Merkel C., Bianco S., Bolognesi M., et al. Effect of triglycyl-lysin-vasopressin on quantitative liver function tests in patients with cirrhosis. American Journal of Gastroenterology 87 (1992) 1580-1586
66. Morelli A., Ertmer C., Lange M., and Westphal M. Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?. Intensive Care Medicine 33 (2007) 1669-1670
67. Michel F., Thomachot L., David M., et al. Continuous low-dose infusion of terlipressin as a rescue therapy in meningococcal septic shock. American Journal of Emergency Medicine 25 (2007) 863 e1-2
68. Umgelter A., Reindl W., Schmid R.M., and Huber W. Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liver. Intensive Care Medicine 34 (2008) 390-391
69. Lange M., Morelli A., Ertmer C., et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 28 (2007) 623-629